The microbiome universe in two maps

A guide to who’s doing what in microbiome therapeutics

In its “big bang” over the last decade, the universe of microbiome therapeutics has expanded far beyond its origins of fecal transplants, used primarily for C. difficile. Mapping biotech activity reveals a broadening range of innovative strategies extending to microbes outside the gut, and a list of 37 indications with active programs.

Companies have flooded into the space since early movers such as Seres Therapeutics Inc., Vedanta Biosciences Inc. and Rebiotix Inc., now part of Ferring Pharmaceuticals A/S, launched about a decade ago.

At least 42 drug developers now have disclosed preclinical or clinical products related to the microbiome, according

Read the full 988 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE